Carlos Buesa

Oncology

Carlos Buesa, CEO of Oryzon Genomics, discusses exploring how epigenetics is reshaping the landscape of oncology and CNS therapies.

News

Chiesi has boosted its rare disease business with an agreement to buy KalVista and Ekterly, its oral drug for treating attacks in rare disease HAE.

Digital

A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.